+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Biosimilar Monoclonal Antibodies Market by Drug Class (Abciximab, Adalimumab, Bevacizumab), Application (Diagnostic, Protein Purification, Therapeutic) - Forecast 2024-2030- Product Image
Global Biosimilar Monoclonal Antibodies Market by Drug Class (Abciximab, Adalimumab, Bevacizumab), Application (Diagnostic, Protein Purification, Therapeutic) - Forecast 2024-2030- Product Image
Sale

Global Biosimilar Monoclonal Antibodies Market by Drug Class (Abciximab, Adalimumab, Bevacizumab), Application (Diagnostic, Protein Purification, Therapeutic) - Forecast 2024-2030

  • PDF Icon

    Report

  • 185 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 4989642
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Biosimilar Monoclonal Antibodies Market size was estimated at USD 7.69 billion in 2023, USD 9.47 billion in 2024, and is expected to grow at a CAGR of 23.19% to reach USD 33.14 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Biosimilar Monoclonal Antibodies Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Biosimilar Monoclonal Antibodies Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Biosimilar Monoclonal Antibodies Market, highlighting leading vendors and their innovative profiles. These include 3SBio Inc., AbbVie, Inc., Amgen Inc., Biocon Limited, BioXpress Therapeutics SA, C.H. Boehringer Sohn AG & Co. KG, Celltrion Healthcare Co Ltd., Coherus BioSciences, Inc., Dr. Reddy’s Laboratories Ltd, Genor BioPharma Co. Ltd, Hisun Pharmaceutical, Intas Pharmaceuticals Limited, Novartis AG, Pfizer, Inc., Reliance Life Sciences, and Samsung Biologics.

Market Segmentation & Coverage

This research report categorizes the Biosimilar Monoclonal Antibodies Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Class
    • Abciximab
    • Adalimumab
    • Bevacizumab
    • Infliximab
    • Rituximab
    • Trastuzumab
  • Application
    • Diagnostic
      • MABs in Biochemical Analysis
        • Cancers
        • Hormonal Disorders
        • Infectious Diseases
        • Pregnancy
      • MABs in Diagnostic Imaging
        • Atherosclerosis
        • Bacterial Infections
        • Cancers
        • Cardiovascular Diseases
        • Deep Vein Thrombosis
    • Protein Purification
    • Therapeutic
      • MABs as Direct Therapeutic Agents
      • MABs as Targeting Agents in Therapy
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the Biosimilar Monoclonal Antibodies Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Biosimilar Monoclonal Antibodies Market?
  3. What are the technology trends and regulatory frameworks in the Biosimilar Monoclonal Antibodies Market?
  4. What is the market share of the leading vendors in the Biosimilar Monoclonal Antibodies Market?
  5. Which modes and strategic moves are suitable for entering the Biosimilar Monoclonal Antibodies Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Biosimilar Monoclonal Antibodies Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of cost-efficient biosimilar monoclonal antibodies
5.1.1.2. Growth in geriatric population and rising incidence of cancer and other chronic diseases
5.1.1.3. Increasing healthcare expenditure in economies
5.1.2. Restraints
5.1.2.1. Government regulations towards the absence of pre-analytical tests
5.1.3. Opportunities
5.1.3.1. Rising number of inorganic strategies for the expansion of production facility
5.1.3.2. Focus on R&D to introduce innovative product pipeline
5.1.4. Challenges
5.1.4.1. Complexities associated with manufacturing processes
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Biosimilar Monoclonal Antibodies Market, by Drug Class
6.1. Introduction
6.2. Abciximab
6.3. Adalimumab
6.4. Bevacizumab
6.5. Infliximab
6.6. Rituximab
6.7. Trastuzumab
7. Biosimilar Monoclonal Antibodies Market, by Application
7.1. Introduction
7.2. Diagnostic
7.3.1. MABs in Biochemical Analysis
7.3.2.1. Cancers
7.3.2.2. Hormonal Disorders
7.3.2.3. Infectious Diseases
7.3.2.4. Pregnancy
7.3.2. MABs in Diagnostic Imaging
7.3.3.1. Atherosclerosis
7.3.3.2. Bacterial Infections
7.3.3.3. Cancers
7.3.3.4. Cardiovascular Diseases
7.3.3.5. Deep Vein Thrombosis
7.3. Protein Purification
7.4. Therapeutic
7.5.1. MABs as Direct Therapeutic Agents
7.5.2. MABs as Targeting Agents in Therapy
8. Americas Biosimilar Monoclonal Antibodies Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Biosimilar Monoclonal Antibodies Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Biosimilar Monoclonal Antibodies Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player
12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. 3SBio Inc.
12.1.2. AbbVie, Inc.
12.1.3. Amgen Inc.
12.1.4. Biocon Limited
12.1.5. BioXpress Therapeutics SA
12.1.6. C.H. Boehringer Sohn AG & Co. KG
12.1.7. Celltrion Healthcare Co Ltd.
12.1.8. Coherus BioSciences, Inc.
12.1.9. Dr. Reddy’s Laboratories Ltd
12.1.10. Genor BioPharma Co. Ltd
12.1.11. Hisun Pharmaceutical
12.1.12. Intas Pharmaceuticals Limited
12.1.13. Novartis AG
12.1.14. Pfizer, Inc.
12.1.15. Reliance Life Sciences
12.1.16. Samsung Biologics
12.2. Key Product Portfolio
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET RESEARCH PROCESS
FIGURE 2. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2023 VS 2030
FIGURE 3. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET DYNAMICS
FIGURE 7. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 8. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 10. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 20. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 6. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ABCIXIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TRASTUZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 13. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 15. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 17. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HORMONAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PREGNANCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 23. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PROTEIN PURIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 31. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS DIRECT THERAPEUTIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS TARGETING AGENTS IN THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 52. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 53. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 54. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 55. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 56. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 57. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 58. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 59. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 60. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 61. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 62. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 63. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 71. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 72. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 73. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 74. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 76. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 78. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 79. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 80. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 81. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 82. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 83. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 84. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 85. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 86. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 87. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 88. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 89. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 90. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 91. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 92. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 93. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 94. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 95. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 96. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 97. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 98. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 99. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 100. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 101. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 102. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 103. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 104. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 105. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 106. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 107. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 108. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 109. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 110. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 111. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 112. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 113. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 114. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 115. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 116. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 117. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 118. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 119. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 120. SINGAPORE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 121. SINGAPORE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 122. SINGAPORE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 123. SINGAPORE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 124. SINGAPORE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 125. SINGAPORE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 126. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 127. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 128. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 129. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 130. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 131. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 132. TAIWAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 133. TAIWAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 134. TAIWAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 135. TAIWAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 136. TAIWAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 137. TAIWAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 138. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 139. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 140. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 141. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 142. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 143. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 144. VIETNAM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 145. VIETNAM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 146. VIETNAM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 147. VIETNAM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 148. VIETNAM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 149. VIETNAM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 157. DENMARK BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 158. DENMARK BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 159. DENMARK BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 160. DENMARK BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 161. DENMARK BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 162. DENMARK BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 163. EGYPT BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 164. EGYPT BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 165. EGYPT BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 166. EGYPT BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 167. EGYPT BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 168. EGYPT BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 169. FINLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 170. FINLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 171. FINLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 172. FINLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 173. FINLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 174. FINLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 175. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 176. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 177. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 178. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 179. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 180. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 181. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 182. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 183. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 184. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 185. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 186. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 187. ISRAEL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 188. ISRAEL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 189. ISRAEL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 190. ISRAEL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 191. ISRAEL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 192. ISRAEL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 193. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 194. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 195. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 196. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 197. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 198. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 205. NIGERIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 211. NORWAY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 212. NORWAY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 213. NORWAY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 214. NORWAY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 215. NORWAY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 216. NORWAY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 217. POLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 218. POLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 219. POLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 220. POLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 221. POLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 222. POLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 223. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 224. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 225. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 226. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 227. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 228. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 229. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 230. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 231. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 234. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 236. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 246. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 247. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 248. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 249. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 250. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 251. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 252. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 265. TURKEY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 266. TURKEY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 267. TURKEY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 268. TURKEY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 269. TURKEY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 270. TURKEY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 271. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 278. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 280. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 282. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 283. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 284. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2023
TABLE 285. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET LICENSE & PRICING

Companies Mentioned

  • 3SBio Inc.
  • AbbVie, Inc.
  • Amgen Inc.
  • Biocon Limited
  • BioXpress Therapeutics SA
  • C.H. Boehringer Sohn AG & Co. KG
  • Celltrion Healthcare Co Ltd.
  • Coherus BioSciences, Inc.
  • Dr. Reddy’s Laboratories Ltd
  • Genor BioPharma Co. Ltd
  • Hisun Pharmaceutical
  • Intas Pharmaceuticals Limited
  • Novartis AG
  • Pfizer, Inc.
  • Reliance Life Sciences
  • Samsung Biologics

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages185
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 9.47 Billion
Forecasted Market Value ( USD ) by 2030 $ 33.14 Billion
Compound Annual Growth Rate23.1%
Regions CoveredGlobal
No. of Companies Mentioned16

Related Topics

Related Reports

Biosimilar Monoclonal Antibodies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F - Product Image

Biosimilar Monoclonal Antibodies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • Report
  • 189 Pages
  • Global
From
Biosimilar Monoclonal Antibody Market By Type, By Indication, By End User: Global Opportunity Analysis and Industry Forecast, 2023-2032 - Product Image

Biosimilar Monoclonal Antibody Market By Type, By Indication, By End User: Global Opportunity Analysis and Industry Forecast, 2023-2032

  • Report
  • 293 Pages
  • Global
From
Biosimilars Market by Drug Class (Drug Class (Monoclonal Antibodies (Adalimumab, Infliximab, Rituximab, Trastuzumab), Insulin, Erythropoietin, Anticoagulants. rhGH), Indication, Region - Global Forecast to 2028 - Product Image

Biosimilars Market by Drug Class (Drug Class (Monoclonal Antibodies (Adalimumab, Infliximab, Rituximab, Trastuzumab), Insulin, Erythropoietin, Anticoagulants. rhGH), Indication, Region - Global Forecast to 2028

  • Report
  • 298 Pages
  • Global
From
Global Biosimilars Market by Product (Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, Recombinant Peptides), Indication (Autoimmune Diseases, Blood Disorders, Chronic Diseases), Manufacturing - Forecast 2024-2030 - Product Image

Global Biosimilars Market by Product (Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, Recombinant Peptides), Indication (Autoimmune Diseases, Blood Disorders, Chronic Diseases), Manufacturing - Forecast 2024-2030

  • Report
  • 195 Pages
  • Global
From
Monoclonal Antibodies (MAs) Global Market Report 2024 - Product Image

Monoclonal Antibodies (MAs) Global Market Report 2024

  • Report
  • 250 Pages
  • Global
From

About the Monoclonal Antibodies Market

Biosimilar Monoclonal Antibodies (mAbs) are biotechnological products that are similar to existing monoclonal antibodies (mAbs) that are already approved for use in humans. Biosimilar mAbs are developed using recombinant DNA technology and are designed to have the same structure and function as the original mAbs. Biosimilar mAbs are used to treat a variety of diseases, including cancer, autoimmune diseases, and infectious diseases. They are also used in research and development of new treatments. The biosimilar mAbs market is growing rapidly due to the increasing demand for mAbs in the treatment of various diseases. The market is expected to continue to grow as more mAbs are developed and approved for use in humans. Additionally, the increasing demand for mAbs in research and development is expected to drive the growth of the market. Some companies in the biosimilar mAbs market include Amgen, Biogen, Merck, Pfizer, and Novartis. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.